The latest price target for Apellis Pharmaceuticals (NASDAQ:APLS) was reported by RBC Capital on January 21, 2025. The analyst firm set a price target for $26.00 expecting APLS to fall to within 12 months (a possible -13.71% downside). 61 analyst firms have reported ratings in the last year.

The latest analyst rating for Apellis Pharmaceuticals (NASDAQ:APLS) was provided by RBC Capital, and Apellis Pharmaceuticals reiterated their sector perform rating.

The last upgrade for Apellis Pharmaceuticals Inc happened on February 5, 2024 when Jefferies raised their price target to $80. Jefferies previously had a hold for Apellis Pharmaceuticals Inc.

The last downgrade for Apellis Pharmaceuticals Inc happened on December 17, 2024 when Goldman Sachs changed their price target from N/A to $36 for Apellis Pharmaceuticals Inc.

Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of Apellis Pharmaceuticals, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for Apellis Pharmaceuticals was filed on January 21, 2025 so you should expect the next rating to be made available sometime around January 21, 2026.

While ratings are subjective and will change, the latest Apellis Pharmaceuticals (APLS) rating was a reiterated with a price target of $26.00 to $26.00. The current price Apellis Pharmaceuticals (APLS) is trading at is $30.13, which is out of the analyst’s predicted range.